Phase III data on HZ/su in Herpes Zoster published in NEJM- GSK

Primary and secondary endpoint data from GlaxoSmithKline’s randomized Phase III trial of HZ/su, a vaccine candidate for the prevention of shingles, was presented at the Conference of the European Society of Clinical Microbiology and Infectious Disease and published in the New England Journal of Medicine. GSK’s HZ/su incorporates Agenus' QS-21 Stimulon adjuvant, which is designed to increase immune response to antigens.

The data show that GSK’s HZ/su reduced the risk of shingles (herpes zoster) by 97.2% in adults aged 50 and older, compared to placebo. Importantly, the protection was maintained across all studied age groups, ranging from 96.6% in subjects aged 50-59, 97.4% in those aged 60-69, and 97.9% in those aged 70 or older. No major safety concerns were identified in the study. The most common reported adverse event was pain at injection site, fatigue and myalgia.